PAR-1 inhibitors: Difference between revisions
New page: Protease Activated Receptor (PAR)-1 inhibitors (also known as thrombin receptor antagonists) are a new class of antiplatelet agents that antagonize platelet activation mediated by thrombin... |
No edit summary |
||
| Line 1: | Line 1: | ||
Protease Activated Receptor (PAR)-1 inhibitors (also known as thrombin receptor antagonists) are a new class of antiplatelet agents that antagonize platelet activation mediated by thrombin, the most potent platelet activator. | Protease Activated Receptor ('''PAR''')-'''1''' '''inhibitors''' (also known as thrombin receptor antagonists) are a new class of antiplatelet agents '''that antagonize platelet activation mediated by thrombin''', the most potent platelet activator. | ||
The cellular actions of thrombin (including the activation of platelets) are mediated by a 7-domain receptor named PAR. The 2 main platelet PAR receptors in humans are PAR-1 and PAR-4, with the former being the principal thrombin receptor. Thrombin cleaves one peptide bond ( | The cellular actions of thrombin (including the activation of platelets) are mediated by a 7-domain receptor named PAR. | ||
The 2 main platelet PAR receptors in humans are PAR-1 and PAR-4, with the former being the principal thrombin receptor. Thrombin cleaves one peptide bond (Arg41-Ser42) of the receptor extracellular domain exposing a new N-terminus, which is called “tethered ligand”. This tethered ligand is the resident agonist of the PARs that ultimately causes its activation. PAR-1 inhibitors selectively block the interaction of the tethered ligand with the activation site, ultimately preventing PAR-1 activation. | |||
The 2 agents in most advanced clinical development are vorapaxar (previously known as SCH530348) and atopaxar (previously known as E-5555). | The 2 agents in most advanced clinical development are vorapaxar (previously known as SCH530348) and atopaxar (previously known as E-5555). | ||
Revision as of 14:14, 25 October 2010
Protease Activated Receptor (PAR)-1 inhibitors (also known as thrombin receptor antagonists) are a new class of antiplatelet agents that antagonize platelet activation mediated by thrombin, the most potent platelet activator. The cellular actions of thrombin (including the activation of platelets) are mediated by a 7-domain receptor named PAR. The 2 main platelet PAR receptors in humans are PAR-1 and PAR-4, with the former being the principal thrombin receptor. Thrombin cleaves one peptide bond (Arg41-Ser42) of the receptor extracellular domain exposing a new N-terminus, which is called “tethered ligand”. This tethered ligand is the resident agonist of the PARs that ultimately causes its activation. PAR-1 inhibitors selectively block the interaction of the tethered ligand with the activation site, ultimately preventing PAR-1 activation. The 2 agents in most advanced clinical development are vorapaxar (previously known as SCH530348) and atopaxar (previously known as E-5555).